Novartis’s Beovu Launch Clouded By Safety Worries
Beovu Uncertainty Should Benefit Regeneron’s Eylea
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.
You may also be interested in...
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.
Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.